NuCana Reports First Quarter 2018 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
NuCana Reports First Quarter 2018 Financial Results

EDINBURGH, United Kingdom, May 23, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA ), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced financial results for the first quarter ended March 31, 2018. 

As of March 31, 2018, NuCana had cash and cash equivalents of £81.3 million compared to £18.3 million as of March 31, 2017.  The increase in cash and cash equivalents primarily reflects the net proceeds raised from NuCana’s initial public offering completed in October 2017.  NuCana reported a loss of £6.4 million for the quarter ended March 31, 2018, compared to £1.6 million for the quarter ended March 31, 2017.  Basic and diluted loss per share was £0.20 for the quarter ended March 31, 2018, compared to £0.07 per share for the comparable quarter in 2017.

“We are off to a great start in 2018 and are advancing multiple product candidates in several important studies,” said Hugh Griffith, NuCana’s Founder and Chief Executive Officer.  “Utilizing our proprietary technology, we are transforming some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  During the quarter, we announced promising interim data from the first eight patients in the Phase 1b study of Acelarin® in combination with cisplatin for the first-line treatment of patients with biliary tract cancers.  One patient had a complete response and three patients had partial responses for an overall response rate of 50%.  We also announced the enrollment of the 100 th patient in the first-line pancreatic cancer Phase 3 study of Acelarin compared to gemcitabine.  We look forward to providing updates on these and our other programs throughout the course of the year.”

About NuCana plc                

NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide ™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Our most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.  Acelarin is currently being evaluated in three clinical studies, including a Phase 2 study for patients with ovarian cancer, a Phase 1b study for patients with biliary tract cancer and a Phase 3 study for patients with pancreatic cancer. NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumors.

For more information, please visit: www.nucana.com .

Forward-Looking Statements

This press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the initiation, timing, progress and results of clinical studies of the Company’s product candidates. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the Securities and Exchange Commission (“SEC”) on March 22, 2018, and subsequent reports that we file with the SEC.  Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

Condensed Consolidated Statements of Operations for the three months ended March 31,
 
  2018    2017 
  (in thousands, except per share data) (unaudited)
  £   £
Research and development expenses (3,705 )   (1,612 )
Administrative expenses (1,240 )   (324 )
Initial public offering related expenses -     (32 )
Net foreign exchange losses (2,548 )   (48 )
Operating loss (7,493 )   (2,016 )
Finance income 190     47  
Loss before tax (7,303 )   (1,969 )
Income tax credit 909     332  
Loss for the period (6,394 )   (1,637 )
       
Basic and diluted loss per share (0.20 )   (0.07 )
           
Condensed Consolidated Statements of Financial Position at March 31,
 
  2018   2017 
  (in thousands) (unaudited)
  £   £
Assets      
Non-current assets      
Intangible assets 2,030     1,585  
Property, plant and equipment 499     16  
Deferred tax asset 40     -  
  2,569     1,601  
Current assets      
Prepayments, accrued income and other receivables 2,799     3,215  
Current income tax receivable 3,265     2,392  
Cash and cash equivalents 81,338     18,323  
  87,402     23,930  
       
Total assets 89,971     25,531  
  Equity and liabilities      
Capital and reserves      
Share capital and share premium 80,508     43,433  
Other reserves 58,494     4,326  
Accumulated deficit (51,553 )   (23,893 )
Total equity attributable to equity holders of the Company 87,449     23,866  
       
Non-current liabilities      
Provisions 18     -  
       
Current liabilities      
Trade payables 897     975  
Payroll taxes and social security 105     65  
Accrued expenditure 1,502     625  
  2,504     1,665  
       
Total liabilities 2,522     1,665  
       
Total equity and liabilities 89,971     25,531  
           
Condensed Consolidated Statements of Cash Flows for the three months ended March 31,
 
  2018   2017  
  (in thousands) (unaudited)
  £   £
Cash flows from operating activities      
Loss for the period (6,394 )   (1,637 )
Adjustments for:      
Income tax credit (909 )   (332 )
Amortization and depreciation 74     31  
Finance income (190 )   (47 )
Share-based payments 428     263  
Net foreign exchange losses 2,537     47  
  (4,454 )   (1,675 )
Movements in working capital:      
Decrease in prepayments, accrued income and other receivables 197     373  
(Decrease) increase in trade payables (222 )   247  
Decrease in payroll taxes, social security and accrued expenditure (190 )   (555 )
Movements in working capital (215 )   65  
Cash used in operations (4,669 )   (1,610 )
Corporation tax 1,910     135  
Net cash used in operating activities (2,759 )   (1,475 )
       
Cash flows from investing activities      
Interest received 202     48  
Payments for office and computer equipment (171 )   (1 )
Payments for intangible assets (136 )   (237 )
Net cash used in investing activities (105 )   (190 )
       
Cash flows from financing activities      
Net cash from financing activities -     -  
Net decrease in cash and cash equivalents (2,864 )   (1,665 )
       
Cash and cash equivalents at beginning of period 86,703     19,990  
Foreign currency translation differences (2,501 )   (2 )
Cash and cash equivalents at end of period 81,338     18,323  

For more information, please contact:

NuCana plc Hugh S. Griffith Chief Executive Officer +44 131 357 1111 info@nucana.com

Westwicke Partners Chris Brinzey +1 339-970-2843 Chris.brinzey@westwicke.com

RooneyPartners Marion Janic +1 212-223-4017 mjanic@rooneyco.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 78

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 37

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Motorsport Games Achieves Significant Growth in Q3 Results

Updated Category News Views 182

Motorsport Games Shows Promising Financial Trends Motorsport Games Inc. (NASDAQ: MSGM) recently shared its financial outcomes for the third quarter, reflecting remarkable growth. The company, a key player in the racing game industry, recorded significant advancements, particularly highlighted by their flagship title, Le Mans Ultimate. For Q3 2025, Motorsport Games...

Continue Reading
AI Giants Converge in Singapore for SuperAI 2026

Updated Category News Views 52

SuperAI Singapore 2026: A Global Gathering Singapore's Marina Bay Sands is buzzing, folks. With 10,000 people crammed into Asia's largest AI event, SuperAI Singapore 2026 is offering up a melting pot of tech brains from 150 countries. It's sold out like your favorite band’s farewell tour—things kicking off with a big bang. A Melting Pot of Innovation You’ve got...

Continue Reading
Investors' Sentiment Towards Terreno Realty Corp Revealed

Updated Category News Views 128

Understanding Investor Sentiment for Terreno Realty Corp Terreno Realty's short interest has notably surged, reflecting a growing sentiment among investors. Currently, 11.02% increase in short interest reveals that now approximately 6.22 million shares are sold short, making it 10.78% of the float. Observing the trading volume suggests that it would take traders roughly...

Continue Reading
Gilead Sciences Targets Growth Amid Oncology Challenges and Opportunities

Updated Category News Views 208

Gilead Sciences faced significant challenges back in 2024 as its oncology ambitions faltered, all while the company leaned heavily on its HIV stronghold. The stock stumbled, reflecting broader market jitters about its future growth potential. You see, Gilead had been riding high on Biktarvy, a blockbuster that held nearly 49% of the U.S. HIV treatment market. Analysts...

Continue Reading
Captify Launches Innovative Election War Room Insights 2024

Updated Category News Views 124

Captify Launches the Election War Room for the 2024 Elections Captify, a leader in real-time audience analytics powered by Search Intelligence, has introduced the Captify Election War Room—a weekly data report that spotlights what people are searching for during the 2024 U.S. election cycle. As the race intensifies, brands and campaign teams want a clearer view of how...

Continue Reading